ROSE-Longitudinal Assessment With Neuroimaging

Part of paid clinical trials in Chicago, Illinois.

Sponsor
State University of New York at Buffalo
Study ID
NCT05089331
Status
Recruiting
Apply to this trial

Conditions

  • Intracerebral Hemorrhage

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date.

Key Dates

Start date
Sep 30, 2020
Status verified
Jul 2025
Primary completion
Mar 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: Participants will be recruited from the GERFHS/ROSE Study
    Participants will be recruited who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study/Recovery and Outcomes from Stroke study, who live in the area of University of Cincinnati, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, Baptist Health Louisville and Houston Methodist. The participant's age must be18 years or greater. The participant or legal representative must be able to provide informed consent, and the racial/ethnic category of participants should be Caucasian, African American or Hispanic.

Primary Outcome Measure

Determination of whether progressive cognitive impairment correlates with CVD and AA markers [ Time Frame: Ongoing/completed by September 2024 ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
University of Illinois ChicagoChicagoIllinois60612
Maureen Hillman
[email protected]
312-355-3863
Fernando Testai, M.D. (PRINCIPAL_INVESTIGATOR)
Baptist Health LouisvilleLouisvilleKentucky40207
Karin Cryan
[email protected]
502-259-5564
Ranjit Bagga, M.D. (PRINCIPAL_INVESTIGATOR)
University of MarylandBaltimoreMaryland21201
Julia Mosher
[email protected]
410-706-1902
Natalie Fecteau
[email protected]
410-706-1902
Steven Kittner, M.D. (PRINCIPAL_INVESTIGATOR)
Columbia UniversityNew YorkNew York10032
Angela Velazquez
[email protected]
212-305-6071
David Roh, M.D. (PRINCIPAL_INVESTIGATOR)
Duke UniversityDurhamNorth Carolina27710
Andreea Podgoreanu
[email protected]
Michael L James, M.D. (PRINCIPAL_INVESTIGATOR)
University of CincinnatiCincinnatiOhio45267
Lee A Gilkerson, RN, BSN
[email protected]
513-558-0122
Tyler P Behymer, BS
[email protected]
513-558-0122
Daniel Woo, M.D.,MS (PRINCIPAL_INVESTIGATOR)
Houston MethodistHoustonTexas77030
Jennifer Meeks, MS
[email protected]
Farhaan Vahidy, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
University of Illinois Chicago· Chicago, ILBaptist Health Louisville· Louisville, KYUniversity of Maryland· Baltimore, MDColumbia University· New York, NYDuke University· Durham, NCUniversity of Cincinnati· Cincinnati, OH

Related Studies